Please note that when a status is noted as "available," this reflects the most current information from the manufacturer but is not an FDA determination that the shortage has been resolved
The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint
Acknowledging that significant weight loss involves psychological adjustment helps set realistic expectations
A frequent query in biochemical databases is what is reta
Blood glucose, food intake, and major tissues including brown adipose, liver, and spleen weights were similar between RETA and SEMA, yet RETA uniquely reduced adiposity and delayed tumor latency suggesting that targeting a single receptor GLP1R was effective for many physiologic and metabolic benefits, but the additional agonism of GIPR and GPCR by RETA uniquely impacted adiposity, tumor onset, and tumor progression
Dosing and administration require attention to detail